PE20181378A1 - DIHYDROQUINOLINE-2-ONA DERIVATIVE BICYCLE COMPOUNDS AS CYP11B INHIBITORS - Google Patents
DIHYDROQUINOLINE-2-ONA DERIVATIVE BICYCLE COMPOUNDS AS CYP11B INHIBITORSInfo
- Publication number
- PE20181378A1 PE20181378A1 PE2018001330A PE2018001330A PE20181378A1 PE 20181378 A1 PE20181378 A1 PE 20181378A1 PE 2018001330 A PE2018001330 A PE 2018001330A PE 2018001330 A PE2018001330 A PE 2018001330A PE 20181378 A1 PE20181378 A1 PE 20181378A1
- Authority
- PE
- Peru
- Prior art keywords
- dihydroquinoline
- cyp11b
- ona
- inhibitors
- derivative
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 title 1
- 101000761960 Homo sapiens Cytochrome P450 11B1, mitochondrial Proteins 0.000 title 1
- 101000761956 Homo sapiens Cytochrome P450 11B2, mitochondrial Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000016998 Conn syndrome Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 125000005347 halocycloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- LVDKZTHQIJVVBW-UHFFFAOYSA-N n-[4-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]ethanesulfonamide Chemical compound CN1C(=O)CCC2=CC(C3=CN=CC4=C3CCCC4NS(=O)(=O)CC)=CC=C21 LVDKZTHQIJVVBW-UHFFFAOYSA-N 0.000 abstract 1
- VDEUDSRUMNAXJG-UHFFFAOYSA-N n-[4-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide Chemical compound CN1C(=O)CCC2=CC(C3=CN=CC4=C3CCCC4NC(=O)CC)=CC=C21 VDEUDSRUMNAXJG-UHFFFAOYSA-N 0.000 abstract 1
- 208000013846 primary aldosteronism Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere compuestos biciclicos derivados de dihidroquinolina-2-ona de formula I en los que R1, R2, R3, R4, R5, R8, R9, R10 son H, alquilo, haloalquilo, cicloalquilo, halocicloalquilo; R6, R7, R12, son H, halogeno, alquilo, haloalquilo, cicloalquilo, entre otros; A1 es N o CR13; A2 es NR14, entre otros; A3 es N o CR17; n es cero, 1 o 2. Dichos compuestos son utiles para terapia o profilaxis de enfermedad renal cronica, fallo cardiaco congestivo, hipertension, aldosteronismo primario, entre otros. Entre los compuestos preferidos tenemos los siguientes: (rac)-N-[4-(1-metil-2-oxo-1,2,3,4-tetrahidro-quinolin-6-il)-5,6,7,8-tetrahidro-isoquinolin-8-il)propionamida; (rac)-N-[4-(1-metil-2-oxo-1,2,3,4-tetrahidroquinolin-6-il)-5,6,7,8-tetrahidroisoquinolin-8-il)etanosulfonamida; entre otros.It refers to bicyclic compounds derived from dihydroquinoline-2-one of formula I in which R1, R2, R3, R4, R5, R8, R9, R10 are H, alkyl, haloalkyl, cycloalkyl, halocycloalkyl; R6, R7, R12, are H, halogen, alkyl, haloalkyl, cycloalkyl, among others; A1 is N or CR13; A2 is NR14, among others; A3 is N or CR17; n is zero, 1 or 2. Said compounds are useful for therapy or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism, among others. Among the preferred compounds we have the following: (rac) -N- [4- (1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl) -5,6,7,8 -tetrahydro-isoquinolin-8-yl) propionamide; (rac) -N- [4- (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl) -5,6,7,8-tetrahydroisoquinolin-8-yl) ethanesulfonamide; among others.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011080078 | 2011-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181378A1 true PE20181378A1 (en) | 2018-09-05 |
Family
ID=46963698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001330A PE20181378A1 (en) | 2011-09-23 | 2012-09-20 | DIHYDROQUINOLINE-2-ONA DERIVATIVE BICYCLE COMPOUNDS AS CYP11B INHIBITORS |
| PE2014000393A PE20141042A1 (en) | 2011-09-23 | 2012-09-20 | NEW BICYCLE DERIVATIVES OF DIHYDROQUINOLINE-2-ONA |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000393A PE20141042A1 (en) | 2011-09-23 | 2012-09-20 | NEW BICYCLE DERIVATIVES OF DIHYDROQUINOLINE-2-ONA |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9353081B2 (en) |
| EP (1) | EP2758388B1 (en) |
| JP (1) | JP6012737B2 (en) |
| KR (1) | KR101723276B1 (en) |
| CN (1) | CN103827101B (en) |
| AR (1) | AR087984A1 (en) |
| AU (1) | AU2012311582B2 (en) |
| BR (1) | BR112014006660B1 (en) |
| CA (1) | CA2845170C (en) |
| CL (1) | CL2014000663A1 (en) |
| CO (1) | CO6870035A2 (en) |
| CR (1) | CR20140089A (en) |
| DK (1) | DK2758388T3 (en) |
| EA (1) | EA035108B1 (en) |
| EC (1) | ECSP14013264A (en) |
| ES (1) | ES2666802T3 (en) |
| HR (1) | HRP20180592T1 (en) |
| HU (1) | HUE038773T2 (en) |
| IL (1) | IL230874A (en) |
| LT (1) | LT2758388T (en) |
| MX (1) | MX366095B (en) |
| MY (1) | MY186165A (en) |
| NO (1) | NO2758388T3 (en) |
| PE (2) | PE20181378A1 (en) |
| PH (1) | PH12014500584A1 (en) |
| PL (1) | PL2758388T3 (en) |
| PT (1) | PT2758388T (en) |
| RS (1) | RS57139B1 (en) |
| SG (1) | SG2014010599A (en) |
| SI (1) | SI2758388T1 (en) |
| TW (1) | TWI576342B (en) |
| UA (1) | UA115972C2 (en) |
| WO (1) | WO2013041591A1 (en) |
| ZA (1) | ZA201401577B (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117092C2 (en) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Amino-substituted imidazopyridazines |
| SI2838883T1 (en) * | 2012-04-17 | 2018-02-28 | F. Hoffmann-La Roche Ag | New phenyl-tetrahydroisoquinoline derivatives |
| WO2014076162A1 (en) | 2012-11-19 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| CA2898349A1 (en) * | 2013-03-14 | 2014-09-18 | F. Hoffmann-La Roche Ag | Dihydroquinoline-2-one derivatives for use as aldosterone synthase inhibitors |
| EP3004076B1 (en) * | 2013-05-27 | 2019-10-23 | F.Hoffmann-La Roche Ag | New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds |
| JP6581970B2 (en) * | 2013-05-27 | 2019-09-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Novel 3,4-dihydro-2H-isoquinolin-1-one and 2,3-dihydro-isoindol-1-one compounds |
| ES2763338T3 (en) * | 2013-05-27 | 2020-05-28 | Hoffmann La Roche | Novel compounds of 3,4-dihydro-2H-isoquinolin-1-one and 2,3-dihydro-isoindol-1-one |
| CA2915788A1 (en) * | 2013-10-17 | 2015-04-23 | F. Hoffmann-La Roche Ag | New phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors |
| EP3057940A1 (en) | 2013-10-17 | 2016-08-24 | F.Hoffmann-La Roche Ag | Phenyl-dihydropyridine derivatives as inhibitors of aldosterone synthase |
| CN105593212B (en) * | 2013-10-17 | 2019-06-04 | 豪夫迈·罗氏有限公司 | Phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors |
| JP6669734B2 (en) * | 2014-10-31 | 2020-03-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Pyrazolyl-3,4-didohydroquinolin-2-one aldosterone synthase inhibitors |
| WO2016066597A1 (en) * | 2014-10-31 | 2016-05-06 | F. Hoffmann-La Roche Ag | New dihydroquinoline pyrazolyl compounds |
| CN106604917B (en) * | 2014-10-31 | 2020-10-09 | 豪夫迈·罗氏有限公司 | Novel dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors |
| US9890171B2 (en) | 2014-12-02 | 2018-02-13 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| CA3026617A1 (en) * | 2016-06-10 | 2017-12-14 | Nihon Medi-Physics Co., Ltd. | Non-invasive diagnostic imaging agent for heart disease |
| US11958818B2 (en) | 2019-05-01 | 2024-04-16 | Boehringer Ingelheim International Gmbh | (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
| JP2024523559A (en) * | 2021-06-24 | 2024-06-28 | シンコア・ファーマ・インコーポレイテッド | How to use aldosterone synthase inhibitors |
| WO2023063851A1 (en) * | 2021-10-13 | 2023-04-20 | «Target Medicals» Limited Liability Company | Inhibitors of human aldosterone synthase (cyp11b2) |
| KR20240122521A (en) | 2021-12-14 | 2024-08-12 | 베링거 인겔하임 인터내셔날 게엠베하 | Aldosterone synthase inhibitors for the treatment of chronic kidney disease |
| EP4580630A1 (en) | 2022-09-02 | 2025-07-09 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| CN119894905A (en) * | 2022-09-23 | 2025-04-25 | 广州威诺森医药科技有限公司 | Bicyclic pyridine steroid synthetase inhibitor and preparation method and application thereof |
| EP4624464A1 (en) * | 2022-11-23 | 2025-10-01 | Shanghai Hansoh Biomedical Co., Ltd. | Pyridine polycyclic compound inhibitor, preparation method therefor and use thereof |
| WO2024222814A1 (en) * | 2023-04-28 | 2024-10-31 | 长春金赛药业有限责任公司 | Cyp11b2 inhibitor compound, pharmaceutical composition and use thereof |
| WO2024235165A1 (en) * | 2023-05-12 | 2024-11-21 | 南京明德新药研发有限公司 | Nitrogen-containing heterocyclic compound and use thereof |
| AU2024310688A1 (en) * | 2023-06-29 | 2026-01-29 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of baxdrostat, and preparation method therefor and use thereof |
| WO2025021062A1 (en) * | 2023-07-21 | 2025-01-30 | 上海翰森生物医药科技有限公司 | Tricyclic compound, and preparation method therefor and use thereof |
| WO2025054172A1 (en) | 2023-09-05 | 2025-03-13 | E-Star Biotech, LLC | Formulations of manp and uses thereof |
| CN117247371A (en) * | 2023-09-18 | 2023-12-19 | 上海相辉医药科技有限公司 | Preparation method of CYP11B2 inhibitor BAXDROSTAT |
| TW202519227A (en) * | 2023-11-10 | 2025-05-16 | 大陸商上海齊魯製藥研究中心有限公司 | Condensed ring derivative, preparation method thereof and application thereof in medicine |
| WO2025125513A1 (en) | 2023-12-15 | 2025-06-19 | AstraZeneca Ireland Limited | Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension |
| CN120289471B (en) * | 2024-03-01 | 2025-10-17 | 浙江扬厉医药技术有限公司 | Pyranopyridine compound, preparation method thereof, pharmaceutical composition and application |
| WO2025256482A1 (en) * | 2024-06-12 | 2025-12-18 | 江苏德源药业股份有限公司 | Pyrido ring compound, preparation therefor and use thereof |
| WO2025261526A1 (en) * | 2024-06-21 | 2025-12-26 | 上海翰森生物医药科技有限公司 | Bis(fused ring) compounds, preparation method therefor and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4792561A (en) * | 1986-05-29 | 1988-12-20 | Syntex (U.S.A.) Inc. | Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors |
| GB8709448D0 (en) * | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
| US5246944A (en) * | 1991-08-13 | 1993-09-21 | Merck & Co., Inc. | Quinoline angiotensin ii antagonists incorporating a substituted benzyl element |
| WO2005065050A2 (en) * | 2003-12-25 | 2005-07-21 | Asahi Kasei Pharma Corporation | Bicyclic compound |
| JP5202327B2 (en) | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | Quinolone-based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions thereof and uses thereof |
| DE102008022221A1 (en) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitors of human aldosterone synthase CYP11B2 |
-
2012
- 2012-09-14 US US13/615,901 patent/US9353081B2/en active Active
- 2012-09-20 EP EP12766628.7A patent/EP2758388B1/en active Active
- 2012-09-20 HR HRP20180592TT patent/HRP20180592T1/en unknown
- 2012-09-20 UA UAA201404207A patent/UA115972C2/en unknown
- 2012-09-20 WO PCT/EP2012/068472 patent/WO2013041591A1/en not_active Ceased
- 2012-09-20 MY MYPI2014700679A patent/MY186165A/en unknown
- 2012-09-20 RS RS20180446A patent/RS57139B1/en unknown
- 2012-09-20 JP JP2014531214A patent/JP6012737B2/en active Active
- 2012-09-20 PE PE2018001330A patent/PE20181378A1/en unknown
- 2012-09-20 ES ES12766628.7T patent/ES2666802T3/en active Active
- 2012-09-20 PH PH1/2014/500584A patent/PH12014500584A1/en unknown
- 2012-09-20 EA EA201490567A patent/EA035108B1/en not_active IP Right Cessation
- 2012-09-20 PT PT127666287T patent/PT2758388T/en unknown
- 2012-09-20 BR BR112014006660-4A patent/BR112014006660B1/en active IP Right Grant
- 2012-09-20 CN CN201280045785.3A patent/CN103827101B/en active Active
- 2012-09-20 CA CA2845170A patent/CA2845170C/en active Active
- 2012-09-20 AU AU2012311582A patent/AU2012311582B2/en active Active
- 2012-09-20 SI SI201231277T patent/SI2758388T1/en unknown
- 2012-09-20 MX MX2014002624A patent/MX366095B/en active IP Right Grant
- 2012-09-20 PE PE2014000393A patent/PE20141042A1/en active IP Right Grant
- 2012-09-20 HU HUE12766628A patent/HUE038773T2/en unknown
- 2012-09-20 DK DK12766628.7T patent/DK2758388T3/en active
- 2012-09-20 SG SG2014010599A patent/SG2014010599A/en unknown
- 2012-09-20 NO NO12766628A patent/NO2758388T3/no unknown
- 2012-09-20 KR KR1020147010662A patent/KR101723276B1/en active Active
- 2012-09-20 PL PL12766628T patent/PL2758388T3/en unknown
- 2012-09-20 LT LTEP12766628.7T patent/LT2758388T/en unknown
- 2012-09-21 AR ARP120103485A patent/AR087984A1/en active IP Right Grant
- 2012-09-21 TW TW101134790A patent/TWI576342B/en active
-
2014
- 2014-01-31 CO CO14020664A patent/CO6870035A2/en active IP Right Grant
- 2014-02-06 IL IL230874A patent/IL230874A/en active IP Right Grant
- 2014-02-25 CR CR20140089A patent/CR20140089A/en unknown
- 2014-02-28 ZA ZA2014/01577A patent/ZA201401577B/en unknown
- 2014-03-19 CL CL2014000663A patent/CL2014000663A1/en unknown
- 2014-03-21 EC ECSP14013264 patent/ECSP14013264A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181378A1 (en) | DIHYDROQUINOLINE-2-ONA DERIVATIVE BICYCLE COMPOUNDS AS CYP11B INHIBITORS | |
| CY1119515T1 (en) | OXAZOL Substituted Indazoles as R3-Kinase Suspensions | |
| EA201791873A1 (en) | POLYMORPH OF SYK INHIBITORS | |
| CR10784A (en) | NEW DERIVATIVES OF AMINOPIRIMIDINE AS PLKI INHIBITORS | |
| CR20120275A (en) | SUBSTITUTED BENZAMIDA DERIVATIVES | |
| PE20161064A1 (en) | DERIVATIVE OF SULFONAMIDE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | |
| EA201401054A1 (en) | N-CYCLILAMIDES AS NEMATOCIDES | |
| AR087148A1 (en) | IMIDAZOPIRIDAZINAS | |
| EA201591360A1 (en) | AZABENZIMADAZLES AS INHIBITORS INHIBITORS PDE4 FOR THE TREATMENT OF THE CNS AND OTHER DISORDERS | |
| MA35664B1 (en) | New bicyclic derivatives of dihydroisoquinolin-1-one | |
| MA34389B1 (en) | NEW AMINOPYRAZOLOQUINAZOLINES | |
| PE20130155A1 (en) | ARYLETINYL DERIVATIVES | |
| CR20110013A (en) | Heteroaryl Derivatives as DGAT1 Inhibitors | |
| PE20151602A1 (en) | SALTS OF DERIVATIVES OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2 (1H) -ONE THAT HAVE AGONISTIC ACTIVITY OF THE B (beta) 2 ADRENERGIC RECEPTOR AS WELL AS ANTAGONIST ACTIVITY OF THE MUSCARINIC RECEPTOR M3 | |
| MA39152B1 (en) | 1,2-substituted cyclopentanes used as orexin receptor antagonists | |
| EA201490272A1 (en) | NEW 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKIRASE INHIBITORS | |
| MA35049B1 (en) | triazolopyridines | |
| AR052866A1 (en) | SUBSTITUTED MONOCICLIC PHENYL-METANONES | |
| PE20170946A1 (en) | 2-AMINO-6- (DIFLUOROMETIL) - 5,5-DIFLUORO-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS | |
| PE20141553A1 (en) | TRIAZOLOPYRIDINE COMPOUNDS AS PED10A INHIBITORS | |
| EA201590438A1 (en) | 2-OXO-2,3-DIHYDROINDOLY FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | |
| ES2568909T3 (en) | Novel neuroquinine receptor antagonist compounds 1 | |
| MA38559B1 (en) | Imidazo-triazine derivatives used as pde10 inhibitors | |
| EA201170074A1 (en) | Isoquinoline derivatives as antagonists of NK3 | |
| BR112014031969A2 (en) | pyrimidinone derivatives as antimalarial agents |